91 related articles for article (PubMed ID: 8611681)
1. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
[TBL] [Abstract][Full Text] [Related]
2. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
[TBL] [Abstract][Full Text] [Related]
3. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
Wagner WM; Ouyang Q; Pawelec G
Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.
Rusakiewicz S; Madrigal A; Travers P; Dodi AI
Cancer Immunol Immunother; 2009 Sep; 58(9):1449-57. PubMed ID: 19360407
[TBL] [Abstract][Full Text] [Related]
5. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.
Held SA; Duchardt KM; Tenzer S; Rückrich T; von Schwarzenberg K; Bringmann A; Kurts C; Schild H; Driessen C; Brossart P; Heine A
Cancer Immunol Immunother; 2013 Apr; 62(4):715-26. PubMed ID: 23184338
[TBL] [Abstract][Full Text] [Related]
7. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
Matsueda S; Yamada A; Takao Y; Tamura M; Komatsu N; Yutani S; Ide T; Sata M; Itoh K
Cancer Immunol Immunother; 2007 Sep; 56(9):1359-66. PubMed ID: 17265020
[TBL] [Abstract][Full Text] [Related]
8. New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Sholikah TA; Hutajulu SH; Sulistyawati D; Aning S; Fatmawati S; Syifarahmah A; Widayati K; Kurnianda J; Paramita DK
Asian Pac J Cancer Prev; 2017 May; 18(5):1343-1348. PubMed ID: 28612580
[TBL] [Abstract][Full Text] [Related]
9. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
[TBL] [Abstract][Full Text] [Related]
10. Identification of peptide epitopes of MAGE-1, -2, -3 that demonstrate HLA-A3-specific binding.
McIntyre CA; Rees RC; Platts KE; Cooke CJ; Smith MO; Mulcahy KA; Murray AK
Cancer Immunol Immunother; 1996 May; 42(4):246-50. PubMed ID: 8665572
[TBL] [Abstract][Full Text] [Related]
11. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley CL; Mathieu MG; Clark RE; McArdle SE; Rees RC
Cancer Immunol Immunother; 2009 Sep; 58(9):1489-99. PubMed ID: 19259670
[TBL] [Abstract][Full Text] [Related]
12. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.
Panya A; Thepmalee C; Sawasdee N; Saengmuang S; Luangwattananun P; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115827. PubMed ID: 37939617
[TBL] [Abstract][Full Text] [Related]
13. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
He H; Kondo Y; Ishiyama K; Alatrash G; Lu S; Cox K; Qiao N; Clise-Dwyer K; St John L; Sukhumalchandra P; Ma Q; Molldrem JJ
Leukemia; 2020 Jun; 34(6):1626-1636. PubMed ID: 31908357
[TBL] [Abstract][Full Text] [Related]
14. Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation.
Racape J; Connan F; Hoebeke J; Choppin J; Guillet JG
Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18208-13. PubMed ID: 17116886
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro.
Pawelec G; Rehbein A; Schlotz E; da Silva P
Cancer Immunol Immunother; 1996 Mar; 42(3):193-9. PubMed ID: 8640848
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
17. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
18. Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.
Hai A; Kizilbash NA; Zaidi SH; Alruwaili J; Shahzad K
Bioinformation; 2014; 10(3):108-14. PubMed ID: 24748748
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.
Gedde-Dahl T; Nilsen E; Thorsby E; Gaudernack G
Cancer Immunol Immunother; 1994 Feb; 38(2):127-34. PubMed ID: 8306368
[TBL] [Abstract][Full Text] [Related]
20. Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2023 Nov; 623(7988):820-827. PubMed ID: 37938771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
